Procalcitonin

Ad Astra Diagnostics receives 510(k) clearance of QScout™ hematology analyzer, the first to report measures of infection and severity at point-of-care

Retrieved on: 
Thursday, November 16, 2023
Sepsis, Food, ICU, Allergy, Hematology, Leukemia, FDA, AAD, COVID-19, Flow cytometry, MD, Infection, NLR, IGS, Granulocyte, White blood cell, Innovation, WBC, Cell, Health, Sparrow Health System, Procalcitonin, Vaccine, Medical device, Research

MORRISVILLE, N.C., Nov. 16, 2023 /PRNewswire/ -- Ad Astra Diagnostics (AAD), developer of rapid diagnostic systems, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its QScout™ rapid-result hematology system, which provides fast, point-of-care white blood cell counts (WBCs), neutrophil-to-lymphocyte ratio, and differentiates the number and percent of five types of mature WBCs as well as immature granulocytes.

Key Points: 
  • QScout™ is the first hematology platform designed for simple, fast operation at the point-of-care.
  • It provides lab-grade, patient-side results to screen for health conditions including infection, leukemia and other blood-related cancers, allergies, and many more.
  • Additionally, NLR is an increasingly important predictor of poor health outcomes, which gained greater use during the pandemic.
  • Sepsis, the body's extreme response to infection, is a life-threatening medical emergency that happens when infection triggers a chain reaction throughout the body.

AACC Releases Guidance on Procalcitonin Testing to Improve Care for Patients with Bacterial Infections

Retrieved on: 
Thursday, May 4, 2023
Hospice and palliative medicine, Urinary tract infection, Antimicrobial stewardship, AACC, DRS, Research, Sepsis, Pharmacist, Food and Drug Administration Amendments Act of 2007, Procalcitonin, Patient, Risk, Confusion, Infection, Mortality, FDA, Food, Medical device, Pharmaceutical industry, Nursing

WASHINGTON, May 4, 2023 /PRNewswire/ -- AACC has issued expert guidance on clinical testing for procalcitonin, a blood marker that helps detect serious bacterial infections and sepsis.

Key Points: 
  • WASHINGTON, May 4, 2023 /PRNewswire/ -- AACC has issued expert guidance on clinical testing for procalcitonin, a blood marker that helps detect serious bacterial infections and sepsis.
  • By giving clinicians and laboratory professionals much-needed clarity on how to best use procalcitonin tests, the new guidelines could improve the treatment of critically ill patients and those with certain lower respiratory infections.
  • Specifically, the guidance document addresses key questions related to the use of procalcitonin to manage adult, pediatric, and newborn patients with suspected sepsis and/or bacterial infections, particularly lower respiratory tract infections.
  • Thus, if procalcitonin testing is used for these groups, the guidance document notes that it's important to establish pediatric reference intervals or define interpretive criteria.

Nanomix Announces Equity Investment from Senior Executive of Woodley Equipment Company, Ltd. at a Premium to Market

Retrieved on: 
Thursday, April 13, 2023
CE, Specialization, Health care, OTCQB, C-reactive protein, Medication, Analyser, PCT, Sepsis, Animal, CRP, Investment, SAN, Point-of-care testing, POC, LAC, Procalcitonin, MHRA, Medical device

To date, Woodley has made a total of $570,000 of equity investments in the Company.

Key Points: 
  • To date, Woodley has made a total of $570,000 of equity investments in the Company.
  • As announced on November 9, 2022 , Nanomix and Woodley entered into an exclusive distribution agreement.
  • Thomas Schlumpberger, Chief Executive Officer of Nanomix, stated, “I am very pleased to receive Woodley’s additional equity investment which shows continued confidence in Nanomix and our technology.
  • Woodley brings significant product development and commercial expertise that allows us to expand our efforts into the veterinary market earlier than planned.

Global Clinical Chemistry Market Forecast Report 2022: A $17.1 Billion Market by 2027 - Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Other Science, Science, Disease, Hospital, COVID-19, Centers for Disease Control and Prevention, Urine, Heart, WHO, Government, Forecast period (finance), Pancreatic cancer, Insight, Conditional sentence, Fully Automated Luxury Communism, Diagnosis, Forecast, Procalcitonin, Prevalence, Diabetes, C-reactive protein, Blood, Fluid mechanics, Cancer, Mortality, Enzyme, Liver disease, CRP, Basic metabolic panel, Neoplasm, Kidney, Incidence, Probability, Exercise, Fine chemical, Medical device, Medical imaging, Pharmaceutical industry, Health insurance, Growth

The "Clinical Chemistry Market, Size, Global Forecast 2023-2027, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Clinical Chemistry Market, Size, Global Forecast 2023-2027, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Clinical chemistry for enzymes frequently reveals information about these things when it comes to disorders like pancreatic cancer or damage to the body's organs.
  • Moreover, for diagnosing cardiac and cancer problems, clinical chemistry also contains assays that serve as heart and tumour markers.
  • Over the coming years, the market for clinical chemistry reagents is expected to expand as more industries use these tools to diagnose various diseases.

Nanomix Enters into Distribution Agreement for the eLab System with Gepa Srl in Italy

Retrieved on: 
Tuesday, November 29, 2022
Growth, SAN, GEPA, CRP, Business manager, Procalcitonin, Health care, PCT, C-reactive protein, Health, Caregiver, POC, ISO 9001:2015, Security (finance), Analyser, MHRA, CE, Point of care, Research, Elab, OTCQB, LAC, Point-of-care testing, Medication, Sepsis, Medical device, Pharmaceutical industry

John Hardesky, Chief Commercial Officer of Nanomix, stated, Gepa has significant experience in this increasingly complex and important segment of critical infections, sepsis, and antibiotic stewardship.

Key Points: 
  • John Hardesky, Chief Commercial Officer of Nanomix, stated, Gepa has significant experience in this increasingly complex and important segment of critical infections, sepsis, and antibiotic stewardship.
  • We are excited to support and align with Gepa on an ambitious execution plan to bring our technology to a competitive market like Italy.
  • Riccardo Figus, Business Manager of Gepa, commented, The GEPA team is very excited to develop the Italian market for the new eLab, a true Point of Care device.
  • The agreement with Nanomix enables us to offer our customers an innovative solution for the fight against sepsis.

Nanomix Enters into an Exclusive Veterinary Distribution Agreement for the eLab System with Woodley Equipment Company, Ltd.

Retrieved on: 
Wednesday, November 9, 2022
SAN, GLOBE, C-reactive protein, CRP, Elab, Dog, Procalcitonin, Forward-looking statement, MHRA, PCT, Health care, U.S. Securities and Exchange Commission, Cat, Health, LAC, Technology, CE, Diagnosis, Specialization, Disease, Sepsis, Mortality, Decision-making, Analyser, Point-of-care testing, Time, Medication, Company, OTCQB, Human, Skin, Contract research organization, Growth, Security (finance), Animal, Infection, Industry, History, POC, Pharmaceutical industry, Medical device

Mike Wickham, Managing Director of Woodley, commented,Woodley supplies equipment for all aspects of laboratory diagnostics in the veterinary market with a specialization in emergency and critical care devices.

Key Points: 
  • Mike Wickham, Managing Director of Woodley, commented,Woodley supplies equipment for all aspects of laboratory diagnostics in the veterinary market with a specialization in emergency and critical care devices.
  • Currently, sepsis in animals has no reliable markers which have a predictive indicator and certainly not at the POC.
  • We are excited that a POC device can be developed to treat animals and Woodley is proud to be involved with Nanomix.
  • The Nanmix eLab system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing.

Nanomix Enters into Multi-Country Distribution Agreement for the eLab System with Mast Group Limited

Retrieved on: 
Friday, November 4, 2022
Public health, Company, Health care, Growth, Medication, Time, CE, SAN, C-reactive protein, Industry, Solution, GLOBE, Elab, POC, PCT, Sepsis, LAC, Point-of-care testing, Health, OTCQB, Infection, MHRA, Microbiology, U.S. Securities and Exchange Commission, Forward-looking statement, Molecular biology, Procalcitonin, Decision-making, Analyser, CRP, Technology, Pneumonia, Pleasure, Marketing, Security (finance), Diagnosis, United Kingdom, Medical device, Pharmaceutical industry

Mast will market and distribute the Nanmix eLabsystem in the United Kingdom, Germany, France, Ireland and South Africa.

Key Points: 
  • Mast will market and distribute the Nanmix eLabsystem in the United Kingdom, Germany, France, Ireland and South Africa.
  • John Hardesky, Chief Commercial Officer of Nanomix, stated, It has been a pleasure working with The Mast Group to bring this agreement to fruition.
  • The Nanmix eLab system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing.
  • Mast Group Ltd.offers its specialized product range through its own companies plus a global network of distributors.

Nanomix Enters into Distribution Agreement for the eLab System with Diaclinic SpA in Chile

Retrieved on: 
Thursday, October 20, 2022
SAN, LAC, Sepsis, Time, U.S. Securities and Exchange Commission, Health care, Growth, MHRA, PCT, Diagnosis, C-reactive protein, Republic, Spondyloarthropathy, Patient, Procalcitonin, Medication, Security (finance), Point-of-care testing, Company, Industry, OTCQB, Health, Elab, CRP, Analyser, CE, Decision-making, GLOBE, Forward-looking statement, Triage, POC, Medical device, Medical imaging, Pharmaceutical industry

We continue to expand our footprint internationally and gain strategic regions due to the unique benefits of the eLab system, stated Thomas Schlumpberger, Chief Executive Officer of Nanomix.

Key Points: 
  • We continue to expand our footprint internationally and gain strategic regions due to the unique benefits of the eLab system, stated Thomas Schlumpberger, Chief Executive Officer of Nanomix.
  • In approximately 12 minutes, the eLab system can provide healthcare professionals accurate and quantitative results without sending samples to a central lab.
  • Additionally, first responders and other healthcare providers can use the eLab for quick, on-the-spot assessment and triage of patients no matter where they are.
  • The Nanmix eLab system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing.

Nanomix Enters into Distribution Agreement for the eLab System and Future New Products with IPS Genomix s.a.l. in the Middle East

Retrieved on: 
Monday, September 12, 2022
Time, PCT, Infection, Critical, Sepsis, Procalcitonin, OTCQB, Company, Health, Growth, Analyser, Industry, Forward-looking statement, U.S. Securities and Exchange Commission, Point-of-care testing, Patient, CRP, Physician, LAC, CE, IPS, MHRA, Diagnosis, C-reactive protein, Elab, SAN, Security (finance), GLOBE, Medication, Decision-making, Health care, Medical device, Pharmaceutical industry

IPS will market and distribute the Nanmix eLab system, including the Nanmix S1 Panel assay and future, new test products for the eLab system, in multiple countries throughout the Middle East.

Key Points: 
  • IPS will market and distribute the Nanmix eLab system, including the Nanmix S1 Panel assay and future, new test products for the eLab system, in multiple countries throughout the Middle East.
  • John Hardesky, Chief Commercial Officer of Nanomix, stated, Adding IPS, and the Middle East, to our growing distribution portfolio will serve Nanomix to accelerate our commercial roll-out of the eLab system.
  • IPS has a long history of successfully introducing new diagnostic technologies to its strong customer base throughout the region.
  • Dr. Thomas Schlumpberger, Chief Executive Officer of Nanomix, said, We are thrilled to work with IPS in rolling out our S-1 Critical Infection assay panel and future products in the Middle East.

Nanomix Announces Agreement with Mobility Health to Co-Develop a Lab Development Test for Evaluating Levels of COVID-19 Circulating Antibodies

Retrieved on: 
Friday, September 2, 2022
Health care, Security (finance), Deen Dayal Mobile Health Clinic, COVID-19, EUA, CEO, Analyser, OTCQB, Safety, Mobility, SAN, Elab, Time, Decision-making, C-reactive protein, Infection, Point-of-care testing, Health, Molecular biology, Forward-looking statement, Medication, U.S. Securities and Exchange Commission, Procalcitonin, PCT, GLOBE, LDT, FDA, Company, Population, MHRA, Sepsis, Growth, Industry, LAC, CRP, Patient, Medical device, Pharmaceutical industry

Nanomix plans to supply the product elements and Mobility Health plans to complete development and validation of the test, with plans to file for a CLIA Lab Emergency Use Authorization (EUA) with the FDA.

Key Points: 
  • Nanomix plans to supply the product elements and Mobility Health plans to complete development and validation of the test, with plans to file for a CLIA Lab Emergency Use Authorization (EUA) with the FDA.
  • Dr. Thomas Schlumpberger, Nanomix CEO, said, We share Mobility Healths mission to transform community healthcare through increased accessibility to healthcare testing and services.
  • The Nanmix eLab system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing.
  • Mobility Health is a biohealth diagnostic company focused on providing accurate, rapid testing of infectious diseases to protect population health and safety.